A composition comprising a therapeutically effective amount of Bidens pilosa extract, or an active compound isolated from the Bidens pilosa extract for use in treating obesity, reducing body weight or body weight gain, and/or gaining muscle mass or muscle content in a subject in need thereof is disclosed. The composition is useful for reducing fat cell size and/or fat accumulation in the fat cell in a subject in need thereof. The composition may further comprises an animal feed. A polyacetylenic compound for use in treating obesity, gaining muscle mass or muscle content, and/or increasing lean tissue protein content in a subject in need thereof is also disclosed. In one embodiment, the polyacetylenic compound is cytopiloyne.
An isolated or a synthetic targeting peptide comprising an amino acid sequence that is at least 90% identical to SEQ ID NO: 8 is disclosed. The targeting peptide may be conjugated to a component selected from the group consisting of polymeric micelles, lipoprotein-based drug carriers, nanoparticle drug carriers, a chemotherapeutic agent, a micelle, a liposome, dendrimers, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a prostate cancer cell, a stem cell, and an imaging agent. Also disclosed are a kit for imaging and detecting the presence of prostate cancer cells in vivo or in vitro, and a composition for treating prostate cancer, inhibiting prostate cancer cell growth, inducing prostate cancer cell cytotoxicity, and/or increasing the survival rate in a prostate cancer patient.
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61K 31/704 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine liés à un système carbocyclique condensé, p. ex. sennosides, thiocolchicosides, escine, daunorubicine, digitoxine
A61K 38/10 - Peptides ayant de 12 à 20 amino-acides
A61K 45/00 - Préparations médicinales contenant des ingrédients actifs non prévus dans les groupes
A61K 47/50 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament
3.
BENEFICIAL EFFECTS OF BIDENS PILOSA ON GUT MICROFLORA AND ANIMAL HEALTH
Beneficial effects of Bidens pilosa on gut microflora and animal health. A composition comprising a therapeutically effective amount of Bidens pilosa extract or an active compound isolated from the Bidens pilosa extract for use in promoting beneficial gut microbiota and/or inhibiting pathogenic gut microbiota in an animal in need thereof is disclosed. In one embodiment, the composition is for use in promoting growth performance or increasing body weight in an animal in need thereof. In another embodiment, the composition is for use in an animal that is not afflicted with coccidiosis.
A61K 31/7048 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'oxygène comme hétéro-atome d'un cycle, p. ex. leucoglucosane, hespéridine, érythromycine, nystatine
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61K 36/11 - Pteridophyta ou filicophyta (fougères)
A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
4.
ANTI-VEGFR2 HUMAN ANTIBODY FOR ANTI-ANGIOGENIC AND TARGETED CANCER THERAPY
An isolated antibody or an antigen-binding fragment thereof having a specific binding affinity to an epitope located within the domain 1 or domain 3 of human vascular endothelial growth factor receptor 2 (VEGFR2; SEQ ID NO: 74) is disclosed. The epitope within the domain 3 of the VEGFR2 is located between amino acid residues 250 and 270 of SEQ ID NO: 74. Use of the antibody or antigen-binding fragment thereof in the manufacture of a medicament for inhibiting tumor growth, tumor angiogenesis, and/or inducing cancer cell cytotoxicity in a subject in need thereof is also disclosed. Also disclosed is a method of detecting the presence of VEGFR2 in a tumor vascular endothelial cell or a cancer cell in a biological sample.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
5.
DEVELOPMENT OF A STANDARDIZED AND EFFECT-OPTIMIZED HERBAL EXTRACT OF WEDELIA CHINENSIS AND ITS USE FOR TREATING DISEASE
A method for preparing a standardized Wedelia chinensis extract and an extract prepared by the method. Also provided is a method for qualifying the standardized extract by characterizing its most abundant compounds and its biological activity in vitro. Additionally, a method is provided for treating an androgen- stimulated disorder with the qualified Wedelia chinensis extract.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A61K 36/28 - Asteraceae ou Compositae (famille de l'aster ou du tournesol), p. ex. camomille, chrysanthème matricaire, achillée ou echinacée
Isolated mutant dengue virus E protein variants are disclosed. The variant comprises an amino acid sequence that is at least 80% identical to SEQ ID NO: 1 and has one or more amino acid residue substitutions at position corresponding to Asn8 (N8), Arg9 (R9), Val12 (V12) and/or Glu13 (E13). The variant may comprise an amino acid sequence that is at least 90% identical to the SEQ ID NO: 1 and lack an infection-enhancing antibody-binding motif comprising the amino acid sequence of SEQ ID NO: 28 at domain I. An isolated nucleic acid sequence encoding the variant, a plasmid expressing the variant, a plasmid expressing a virus-like particle comprising the variant, a DNA vaccine, and a method of detecting the presence of a dengue virus in a biological sample are also disclosed.
A61K 38/00 - Préparations médicinales contenant des peptides
C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
8.
A SYSTEM FOR OBTAINING BIOMLECULAR MEASURES BASED ON PIEZOELECTRIC TECHNOLOGY
A system for detecting various biomolecular measures is provided. The system has a biosensor device comprising a piezoelectric material, at least one conductive layer formed over the piezoelectric material, and at least one surface modified polymer layer formed over the piezoelectric material, wherein the at least one surface modified polymer layer is characterized by surface roughness of about under 10nm peak to peak, a hydrophobicity with a contact angle of at least 94 or a combination thereof. The system also has a sampling cascade comprising a hydrophobic housing with a sample presenting area and at least one recess adjacent to the sample presenting area for accommodating the biosensor device therein, and a hydrophilic holder formed on the sample presenting area for holding the liquid sample therein.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
9.
ANTIBODIES AGAINST PATHOLOGICAL FORMS OF TDP-43 AND USES THEREOF
Disclosed herein are novel pathological form of TDP-43, monoclonal antibodies against such pathological form of TDP-43, and uses thereof. The novel pathological form of TDP-43 is characterized in having a spherical particle size of about 2 to 400 nm in diameter. A second aspect of this disclosure to provide a use of an antibody for manufacturing a medicament or a pharmaceutical composition for the prophylaxis or treatment of a TDP-43 oligomer associated disease.
A Pdia4 inhibitor for use in preventing, alleviating and/or treating diabetes and/or diabetes-related complications in a subject in need thereof is disclosed, wherein the Pdia4 inhibitor does not comprise cytopiloyene. A Pdia4 inhibitor and one other anti-diabetic agent for use in combination therapy in preventing, alleviating, treating diabetes and diabetes-related complications, and/or reversing diabetes in a subject in need thereof is also disclosed, wherein the Pdia4 inhibitors for use in combination therapy may comprise cytopiloyene. Also disclosed are methods for diagnosing, treating and monitoring diabetes, and methods of screening for a Pdia4 inhibitor and/or an anti-diabetic agent.
A61K 31/7036 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques liés à un composé carbocyclique, p. ex. phloridzine ayant au moins un groupe amino lié directement au carbocycle, p. ex. streptomycine, gentamycine, amikacine, validamycine, fortimicines
A61K 31/7028 - Composés ayant des radicaux saccharide liés à des composés non-saccharide par des liaisons glycosidiques
11.
METHODS FOR FULL-LENGTH AMPLIFICATION OF DOUBLE-STRANDED LINEAR NUCLEIC ACIDS OF UNKNOWN SEQUENCES
An adaptor for use in amplifying all linear, double-stranded nucleic acid molecules of unknown sequences in a sample is disclosed. The adaptor consists of: (1) the first oligonucleotide (P- oligo) with a phosphate at the 5'end and without an additional thymine nucleotide at the 3' end; and (2) the second oligonucleotide (T~oligo) with an extra 3'-T and without a 5'-phosphate. The P-oligo and T-oligo are complementary to each other except at the 3' -T (thymine) in the T-oligo. The adaptor is ligated to nucleic acids of unknown sequences which have an extra A in the 3' end (3 ' ~A overhang) to form adaptor-ligated target nucleic acids. The T-oligo is then employed as a single primer for T-oligo-primed polymerase chain reaction (TOP-PCR) and amplifies the nucleic acids of unknown sequences in full-length.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
12.
COMPOUNDS FOR USE IN PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES AND PAIN
Compounds for use in prevention and treatment of neurodegenerative disease and pain are disclosed. In one embodiment of the invention, the compound is selected from the group consisting of N6-[(3-halothien-2-yl)methyl]adenosine, N6-[(4-halothien-2-yl)methyl]adenosine, and N6-[(5-halothien-2-yl)methyl]adenosine. In another embodiment of the invention, the compound is selected from the group consisting of N6-[(2-bromothien-3-yl)methyl]adenosine, N6-[(4-bromothien-3-yl)methyl]adenosine, N6-[(5-bromothien-3-yl)methyl]adenosine N6-[(2-chlorothien-3-yl)methyl]adenosine, N6-[(4-chlorothien-3-yl)methyl]adenosine, and N6-[(5-chlorothien-3-yl)methyl]adenosine. Also disclosed are methods of making and using the same.
C07D 498/02 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient deux hétérocycles
C07D 515/02 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient deux hétérocycles
13.
METHOD FOR PRODUCING SEGMENTAL ANEUPLOIDY (SAN) STRAINS OF TRICHODERMA REESEI VIA SEXUAL CROSSING AND SAN STRAINS PRODUCED THEREFROM
The present invention relates to a technology to provide segmental aneuploidy progeny strains of Trichoderma reesei. In particular, the present invention relates to a method to produce segmental aneuploidy progeny strains of Trichoderma reesei via sexual crossing of two parent haploid strains with chromosome heterozygosity (e.g. one having scaffold M and scaffold 33, the other having scaffold F and scaffold X), preferably at least one of which includes a non-homologous end joining (NHEJ) gene. The present invention also relates to stable, segmental aneuploidy progeny strains of richoderma reesei thus produced which particularly exhibit enhanced gene expression or activities of carbohydrate- active enzymes (CAZymes) and more particularly prevent returning to euploidy for an extended period of time.
A fusion gene encoding M. taiwanensis WR-220 keratinase is disclosed. The fusion comprises: (a) a first DNA sequence encoding a protein secretion signal peptide, located at the N-terminus of the fusion gene; (b) a second DNA sequence encoding an inhibitory domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the first DNA sequence; and (c) a third DNA sequence encoding encoding a catalytic domain of M. taiwanensis WR-220 keratinase, linked in translation frame with the second DNA sequence, wherein the fusion gene is a non-naturally occurring chimeric DNA. Also disclosed are a method for preparation of the catalytic domain of M. taiwanensis WR-220 keratinase, and use of the M. taiwanensis WR-220 keratinase.
The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor.
C07C 47/34 - Composés saturés comportant des groupes —CHO liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons polycycliques
C07C 47/33 - Composés saturés comportant des groupes —CHO liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un cycle de sept à douze chaînons
C07C 47/36 - Composés saturés comportant des groupes —CHO liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons contenant des groupes hydroxyle
C07C 62/38 - Composés non saturés contenant des groupes cétone
The present disclosure provides methods of preparing glucagon-like peptide-1 (GLP-1) receptor modulators, such as compounds of Formula (II) or (VI), or intermediates thereof. The compounds that may be prepared by the described methods are useful for regulating blood glucose levels and/or treating a disease mediated by a GLP-1 receptor (e.g.diabetes).
C07C 45/27 - Préparation de composés comportant des groupes C=O liés uniquement à des atomes de carbone ou d'hydrogènePréparation des chélates de ces composés par oxydation
C07C 47/43 - Composés non saturés comportant des groupes —CHO liés à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons d'un cycle de sept à douze chaînons
C07C 49/413 - Composés saturés comportant un groupe cétone faisant partie d'un cycle d'un cycle de sept à douze chaînons
17.
ANTIMICROBIAL PEPTIDES DERIVED FROM HEPATITIS B VIRUS CORE PROTEIN ARGININE-RICH DOMAIN
A pharmaceutical composition for use in killing and/or inhibiting the growth and/or proliferation of a microorganism in a subject in need thereof, or for treating a subject afflicted with a microbial infection is disclosed. The composition comprises: (a) an effective amount of an isolated peptide, wherein the peptide comprises the arginine-rich carboxy-terminal region of hepatitis B virus core protein (HBc) and exhibits an antimicrobial activity; and (b) a pharmaceutically acceptable carrier. The peptide exhibits an activity against Gram-negative bacteria, Gram-positive bacteria, and/or fungi.
A01N 37/18 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés organiques comportant un atome de carbone possédant trois liaisons à des hétéro-atomes, avec au plus deux liaisons à un halogène, p. ex. acides carboxyliques contenant le groupe —CO—N, p. ex. amides ou imides d'acide carboxyliqueLeurs thio-analogues
NATIONAL TAIWAN UNIVERSITY (Taïwan, Province de Chine)
LIANG, Chi-Ming (USA)
Inventeur(s)
Chen, Ching-Chow
Chen, Jhih-Bin
Wei, Tzu-Tang
Lin, Jung-Hsin
Fang, Jim-Min
Chern, Ting-Rong
Abrégé
The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.
C07C 235/26 - Amides d'acides carboxyliques, le squelette carboné de la partie acide étant substitué de plus par des atomes d'oxygène ayant des atomes de carbone de groupes carboxamide liés à des atomes de carbone acycliques et des atomes d'oxygène, liés par des liaisons simples, liés au même squelette carboné le squelette carboné étant saturé et contenant des cycles
Method of regulating the stability and/or the level of the fusion protein PLZF/RARA are disclosed. Also disclosed are methods for identifying an agent as a regulator of the stability and/or the level of the fusion protein PLZF/RARA. Methods for identifying a therapeutic agent for treating PLZF/RARA-associated acute promyelocytic leukemia (APL) is also disclosed.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/574 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour le cancer
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
20.
DIAMINOBENZOIC OR ORTHO-PHENYLENE DIAMINE CONJUGATED PEPTIDES AS FUNCTIONAL SACCHARIDE TAGGING REAGENTS
Novel designs of tagged saccharides useful in analytical and diagnostic applications are disclosed. Saccharide reagents disclosed mclude monosaccharide, oligosaccharide or polysaccharide subanit is coupled at the reducing end to a tagging moiety comprising an ortho-diaminobenzoic(DAB)-peptide, The tagged saccharide comprising detectable or functional groups coupled to the DAB-peptide entity are provided. Methods for use of the tagged saccharides as reagents for chromatography and mass spectrometry are disclosed.
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
21.
ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (EpCAM) comprising the amino acid sequence of SEQ ID NO: 1; (b) having a specific binding affinity to cancer cells expressing EpCAM, said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (NPC), colorectal cancer cells, and ovarian cancer cells; and(c) having no binding affinity to human umbilical vein endothelial cell (HUVEC) and normal nasal mucosal epithelia (NNM). Also disclosed is an isolated monoclonal antibody or an antigen-binding fragment thereof that has a specific binding affinity to an epitope within the sequence of KPEGALQNNDGLYDPDCDE (SEQ ID NO: 63) located within the EGF-like domain II of epithelial cell adhesion molecule (EpCAM). Methods of using the same are also disclosed.
A composition for use in prevention, inhibition and/or treatment of coccidiosis in an animal is disclosed. The composition comprises an effective amount of Bidens pilosa, an active constituent thereof, or an active compound isolated therefrom. In another aspect, a composition for use in preventing and/or treating coccidiosis, and/or enhancing growth in an animal is disclosed, the composition comprising an animal feed and an effective amount of Bidens pilosa, or an isolated active constituent comprising a polyacetylenic compound.
A61K 36/00 - Préparations médicinales de constitution indéterminée contenant du matériel provenant d'algues, de lichens, de champignons, ou de plantes, ou leurs dérivés, p. ex. médicaments traditionnels à base de plantes
A01N 25/08 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, caractérisés par leurs formes, ingrédients inactifs ou modes d'applicationSubstances réduisant les effets nocifs des ingrédients actifs vis-à-vis d'organismes autres que les animaux nuisibles contenant des solides comme supports ou diluants
Antibodies that bind to c-Met are provided herein, as well as related compositions and methods of use. Methods of use encompass cancer therapies and diagnostics. In certain embodiments, antibodies bind mammalian cell surface antigen (e.g., cancer cell surface antigen). The antibodies can also be endocytosed upon binding to cells. Cells that can be targeted by the antibodies include carcinomas, such as those in lung, kidney, liver, stomach, breast, and brain, etc.
A system includes a displacement sensor, an actuator connected to the displacement sensor, and a feedback unit. The displacement sensor is configured to measure at least one of a relative position and a relative orientation between the displacement sensor and the target object. The feedback unit receives a signal from the displacement sensor related to the measured relative position or relative orientation and controls the actuator to move the displacement sensor on the basis of variations in the received signal arising due to a change in environmental conditions.
G01B 21/32 - Dispositions pour la mesure ou leurs détails, où la technique de mesure n'est pas couverte par les autres groupes de la présente sous-classe, est non spécifiée ou est non significative pour mesurer la déformation dans un solide
Detecting presence of cancer cells in a subject using one or more of fibronectin 1, S100 calcium binding protein A7, and carboxy-terminal domain (RNA polymerase II, polypeptide A) small phosphatase-like protein as a marker.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/12 - Gènes codant pour des protéines animales
26.
EXTRACELLULAR PLANT FERREDOXIN-LIKE PROTEIN AND USES THEREOF
Disclosed are polypeptides, nucleic acids, and related compositions that render plants resistant to bacterial pathogens. Also disclosed are transgenic plants having the nucleic acids and resistant to bacterial pathogens.
A01H 5/00 - Angiospermes, c.-à-d. plantes à fleurs, caractérisées par leurs parties végétalesAngiospermes caractérisées autrement que par leur taxonomie botanique
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
C12N 15/29 - Gènes codant pour des protéines végétales, p. ex. thaumatine
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
brevets